Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis
Recurrent VTE · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in recurrent VTE compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.46 [0.16, 1.32]1 study · 270 participantsLow